Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated:  4/5/2016
Massachusetts General Hosptial
mi
from
Boston, MA
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated: 4/5/2016
Massachusetts General Hosptial
mi
from
Boston, MA
Click here to add this to my saved trials
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated:  4/5/2016
New York Presbyterian/Columbia University Medical Center
mi
from
New York, NY
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated: 4/5/2016
New York Presbyterian/Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated:  4/5/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated: 4/5/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated:  4/5/2016
University of Virginia
mi
from
Charlottesville, VA
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated: 4/5/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated:  4/5/2016
University of Massachusetts Worcester
mi
from
Worcester, MA
Amgen 386 for Recurrent Glioblastoma
Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
Status: Enrolling
Updated: 4/5/2016
University of Massachusetts Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
Dexanabinol in Patients With Brain Cancer
A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer
Status: Enrolling
Updated:  4/9/2016
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Dexanabinol in Patients With Brain Cancer
A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer
Status: Enrolling
Updated: 4/9/2016
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated:  4/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated: 4/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated:  4/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated: 4/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated:  4/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling
Updated: 4/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Los Angeles, CA
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Boston, MA
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Cincinnati, OH
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated:  4/14/2016
Research Site
mi
from
Parkville,
AMG 595 First-in-Human in Recurrent Gliomas
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Status: Enrolling
Updated: 4/14/2016
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma
A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  4/15/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma
A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 4/15/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma
Status: Enrolling
Updated:  4/16/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma
Status: Enrolling
Updated: 4/16/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO Grade IV Malignant Glioma
Status: Enrolling
Updated:  4/19/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO Grade IV Malignant Glioma
Status: Enrolling
Updated: 4/19/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Stereotactic Body Radiotherapy for Spine Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors
Status: Enrolling
Updated:  4/20/2016
St. John's Mercy Medical Center
mi
from
St. Louis, MO
Stereotactic Body Radiotherapy for Spine Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors
Status: Enrolling
Updated: 4/20/2016
St. John's Mercy Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated:  4/20/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated: 4/20/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated:  4/20/2016
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated: 4/20/2016
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma
Status: Enrolling
Updated:  4/21/2016
Columbia Presbyterian Medical Center, Morgan Stanley Children's Hospital New York Presbyterian
mi
from
New York, NY
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma
Status: Enrolling
Updated: 4/21/2016
Columbia Presbyterian Medical Center, Morgan Stanley Children's Hospital New York Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Columbia University Medical Center
mi
from
New York, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide
Status: Enrolling
Updated:  5/4/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide
Status: Enrolling
Updated: 5/4/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Studying Chromosomes in Samples From Younger Patients With Neuroblastoma
Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Studying Chromosomes in Samples From Younger Patients With Neuroblastoma
Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery and Plasticity Following Brain Tumor Surgery in or Adjacent to Eloquent Cortex
Status: Enrolling
Updated:  5/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery and Plasticity Following Brain Tumor Surgery in or Adjacent to Eloquent Cortex
Status: Enrolling
Updated: 5/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Expanded Access to ANG1005 for Individual Patients
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma.
Status: Enrolling
Updated:  5/19/2016
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Expanded Access to ANG1005 for Individual Patients
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma.
Status: Enrolling
Updated: 5/19/2016
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Cellular Immunotherapy Study for Brain Cancer
A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas
Status: Enrolling
Updated:  5/26/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Cellular Immunotherapy Study for Brain Cancer
A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas
Status: Enrolling
Updated: 5/26/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  6/2/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 6/2/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Status: Enrolling
Updated:  6/2/2016
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Status: Enrolling
Updated: 6/2/2016
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated:  6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated: 6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  6/8/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 6/8/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Status: Enrolling
Updated:  6/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Status: Enrolling
Updated: 6/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated:  6/14/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated: 6/14/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated:  6/14/2016
Henry Ford Hospital
mi
from
Detroit, MI
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated: 6/14/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated:  6/14/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated: 6/14/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated:  6/14/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated: 6/14/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated:  6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
Status: Enrolling
Updated: 6/14/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
PET Imaging of Intracranial Cancers With 18F-FSPG
An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers
Status: Enrolling
Updated:  6/16/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
PET Imaging of Intracranial Cancers With 18F-FSPG
An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers
Status: Enrolling
Updated: 6/16/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated:  6/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated: 6/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated:  6/20/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated: 6/20/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated:  6/20/2016
Children's Medical Center Dallas, Center for Cancer and Blood Disorders
mi
from
Dallas, TX
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated: 6/20/2016
Children's Medical Center Dallas, Center for Cancer and Blood Disorders
mi
from
Dallas, TX
Click here to add this to my saved trials
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated:  6/20/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated: 6/20/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated:  6/20/2016
Texas Children's Hospital
mi
from
Houston, TX
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas
Status: Enrolling
Updated: 6/20/2016
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials